Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Biogen’s $7.3 Bln acquisition of Reata followed bidding war

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Aug 15, 2023 11:36pm

208 Views

Post# 35590332

RE:RE:Biogen’s $7.3 Bln acquisition of Reata followed bidding war

Here's some further reality ..Biogen paid US$7.3 Billion for a niche product Biopharmaceutical company.

Now think about why ONCY is worth US$10+ Billion and more with 2 Phase 3 ready clinical trials in orphan / rare disease indications with unmet medical needs.

Enhertu is still not indicated forER+/ HER2- mBC - just low HER2 and an Accelerated Approval for pelareorep in mBC can be achieved on the ORR and PFS surrogate endpoints/ biomarkers that ONCY has reported in its August 14th press release.

<< Previous

Bullboard Posts

Next >>

A PGM mining stock with value written all over it